Relay Therapeutics Inc (RLAY) concluded trading on Wednesday at a closing price of $3.33, with 4.07 million shares of worth about $13.56 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -44.68% during that period and on April 30, 2025 the price saw a gain of about 7.42%. Currently the company’s common shares owned by public are about 167.76M shares, out of which, 128.50M shares are available for trading.
Stock saw a price change of 7.07% in past 5 days and over the past one month there was a price change of 27.10%. Year-to-date (YTD), RLAY shares are showing a performance of -19.17% which decreased to -47.72% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.77 but also hit the highest price of $10.72 during that period. The average intraday trading volume for Relay Therapeutics Inc shares is 2.27 million. The stock is currently trading 25.02% above its 20-day simple moving average (SMA20), while that difference is up 8.28% for SMA50 and it goes to -36.89% lower than SMA200.
Relay Therapeutics Inc (NASDAQ: RLAY) currently have 167.76M outstanding shares and institutions hold larger chunk of about 79.61% of that.
The stock has a current market capitalization of $567.73M and its 3Y-monthly beta is at 1.66. It has posted earnings per share of -$2.40 in the same period. It has Quick Ratio of 15.95 while making debt-to-equity ratio of 0.06. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for RLAY, volatility over the week remained 8.90% while standing at 10.87% over the month.
Stock’s fiscal year EPS is expected to rise by 12.43% while it is estimated to decrease by -3.98% in next year. EPS is likely to grow at an annualized rate of 2.09% for next 5-years, compared to annual growth of -23.05% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Wells Fargo on April 17, 2025 offering an Equal weight rating for the stock and assigned a target price of $4 to it. Coverage by Jefferies stated Relay Therapeutics Inc (RLAY) stock as a Buy in their note to investors on September 10, 2024, suggesting a price target of $16 for the stock. Stock get an Overweight rating from Barclays on May 10, 2024.
